Banque Cantonale Vaudoise Boosts Stake in Boston Scientific Corporation $BSX

Banque Cantonale Vaudoise raised its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 60.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 66,323 shares of the medical equipment provider’s stock after acquiring an additional 25,106 shares during the quarter. Banque Cantonale Vaudoise’s holdings in Boston Scientific were worth $4,162,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the stock. Assenagon Asset Management S.A. grew its holdings in Boston Scientific by 133.6% in the first quarter. Assenagon Asset Management S.A. now owns 10,057,936 shares of the medical equipment provider’s stock worth $631,135,000 after purchasing an additional 5,751,760 shares during the last quarter. Signal Advisors Wealth LLC raised its holdings in shares of Boston Scientific by 6.6% in the first quarter. Signal Advisors Wealth LLC now owns 4,504 shares of the medical equipment provider’s stock worth $283,000 after buying an additional 280 shares during the last quarter. Robbins Farley increased its holdings in shares of Boston Scientific by 3.7% in the first quarter. Robbins Farley now owns 44,130 shares of the medical equipment provider’s stock valued at $2,769,000 after purchasing an additional 1,591 shares during the period. AdvisorNet Financial Inc raised its stake in shares of Boston Scientific by 48.7% in the first quarter. AdvisorNet Financial Inc now owns 8,731 shares of the medical equipment provider’s stock worth $548,000 after purchasing an additional 2,858 shares during the last quarter. Finally, Anchyra Partners LLC lifted its holdings in shares of Boston Scientific by 32.7% during the first quarter. Anchyra Partners LLC now owns 5,379 shares of the medical equipment provider’s stock worth $338,000 after purchasing an additional 1,324 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Jefferies kept a Buy rating on Boston Scientific and still sees upside, even after cutting its price target to $67 from $100. Piper Sandler also maintained an Overweight rating, suggesting some analysts remain constructive on the long-term story.
• Positive Sentiment: Analyst coverage continues to frame BSX as oversold with potential upside, which may help support investor confidence if the company can avoid further setbacks.
• Neutral Sentiment: Recent market commentary noted Boston Scientific has been trading well below prior levels, with investors reassessing valuation after the sharp move lower.
• Negative Sentiment: Boston Scientific disclosed a nationwide, firm-initiated recall of Orca Single Use Air/Water and Suction Valves after reports that suction buttons could stick during gastrointestinal endoscopy procedures. The FDA classified the action as a Class II recall, which raises quality-control and regulatory concerns.
• Negative Sentiment: The recall adds to investor worries that even smaller accessory-device issues can hurt operations, increase oversight costs, and pressure sentiment around the company’s medical-device portfolio.
• Negative Sentiment: Options activity also turned more cautious, with unusual buying of put options suggesting some traders are positioning for additional downside in BSX.
• Negative Sentiment: Commentary from Jim Cramer added to the bearish tone, saying the sector is “too hard to own” right now and expressing surprise at the decline in Boston Scientific shares.

Insider Buying and Selling at Boston Scientific

In related news, Director David C. Habiger acquired 2,250 shares of the firm’s stock in a transaction on Wednesday, May 20th. The shares were acquired at an average cost of $55.92 per share, with a total value of $125,820.00. Following the completion of the acquisition, the director directly owned 13,878 shares in the company, valued at approximately $776,057.76. This trade represents a 19.35% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Edward J. Ludwig bought 3,580 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were bought at an average cost of $56.68 per share, with a total value of $202,914.40. Following the purchase, the director directly owned 25,359 shares of the company’s stock, valued at approximately $1,437,348.12. This represents a 16.44% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 9,800 shares of company stock valued at $554,012 over the last ninety days. Corporate insiders own 0.34% of the company’s stock.

Boston Scientific Stock Down 2.8%

Boston Scientific stock opened at $44.34 on Thursday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The stock has a market capitalization of $65.90 billion, a PE ratio of 18.55, a price-to-earnings-growth ratio of 0.87 and a beta of 0.56. The business has a 50 day simple moving average of $53.67 and a 200-day simple moving average of $71.70. Boston Scientific Corporation has a 12 month low of $44.05 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. During the same quarter last year, the firm posted $0.75 EPS. The business’s revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, analysts anticipate that Boston Scientific Corporation will post 3.36 EPS for the current fiscal year.

Boston Scientific declared that its board has approved a stock buyback plan on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board believes its shares are undervalued.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on BSX. Truist Financial cut their price target on shares of Boston Scientific from $85.00 to $64.00 and set a “buy” rating on the stock in a report on Thursday, June 4th. UBS Group decreased their price objective on shares of Boston Scientific from $120.00 to $105.00 and set a “buy” rating for the company in a research note on Tuesday, March 17th. Zacks Research downgraded shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a research report on Friday, June 5th. Citigroup lowered their price target on shares of Boston Scientific from $87.00 to $70.00 and set a “buy” rating on the stock in a report on Thursday, May 28th. Finally, Barclays decreased their price objective on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a report on Thursday, May 28th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $83.76.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.